RemedyOne, Author at RemedyOne

Webinar On-Demand: Breaking Down the Hottest Topic in Pharmacy: Humira Biosimilars

Uncover what could happen with Humira and the biosimilar market in 2023 While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market. Will biosimilar competitors increase competition, lower drug costs and knock Humira …

Webinar On-Demand: Breaking Down the Hottest Topic in Pharmacy: Humira Biosimilars Read More »

Potent Veterinary Drug Resistant to Narcan and It’s Rising Illicit Use Among Humans – RemedyOne’s Rob Louie Quoted in an Insightful Analysis with Fox News

Clinical Insights, News / By RemedyOne

A Fox News article recently quoted RemedyOne EVP of clinical services Rob Louie on xylazine, a potent veterinary drug that has seen a recent uptick in illicit human use. Rob helped add context to an alert from the U.S. Drug Enforcement Administration on xylazine. Below is the complete interview, which Rob prepared for in collaboration …

Potent Veterinary Drug Resistant to Narcan and It’s Rising Illicit Use Among Humans – RemedyOne’s Rob Louie Quoted in an Insightful Analysis with Fox News Read More »

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars

Clinical Insights, Formulary Management / By RemedyOne

The industry report you’ve been waiting for. Today biosimilars seem to be the topic of conversation everywhere. Why? Humira. The launch of Humira biosimilars will be a test for industry stakeholders, as their entrance will reveal whether blockbuster drugs—that offer significant rebates—can be replaced to reduce the cost burden on patients and payers in the United States. Download our …

Whitepaper: Breaking Down the Hottest Topic in Pharmacy—Humira Biosimilars Read More »

Unpacking the Biosimilar Buzz

Clinical Insights, Formulary Management / By RemedyOne

As industry experts, it’s the number one topic we’re being asked to comment on. While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market. Will biosimilar competitors increase competition, lower drug costs and …

Unpacking the Biosimilar Buzz Read More »

2022 Q1 RemedyOne Quarterly Pipeline Report

Clinical Insights / By RemedyOne

Download our 2022 Q1 Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful tool for your team to keep updated on the latest …

2022 Q1 RemedyOne Quarterly Pipeline Report Read More »

2021 Q4 RemedyOne Quarterly Pipeline Report

Clinical Insights / By RemedyOne

Download our 2021 Q4 Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful tool for your team to keep updated on the latest …

2021 Q4 RemedyOne Quarterly Pipeline Report Read More »

Uncovering Solutions for Affordable Drug Pricing

Formulary Management / By RemedyOne

The House Committee on Oversight and Reform held a series of hearings to review findings from an in-depth investigation into drug pricing actions that was conducted last year with CEOs representing some of the largest and most profitable pharmaceutical manufacturers. As stated in the summary report of the investigation by Chairwoman Carolyn Maloney, “the drug …

Uncovering Solutions for Affordable Drug Pricing Read More »

RemedyOne Drug Spotlight: Rukobia

Clinical Insights, Formulary Management / By RemedyOne

Rukobia (fostemasavir) There are an estimated 2 million people living with the human immunodeficiency virus (HIV) in the United States. In 2018, there were close to 36,000 new cases of HIV diagnoses in the U.S. Since the introduction of antiretroviral therapy (ART), the HIV incidence has decreased as a result of decreased transmission and readily …

RemedyOne Drug Spotlight: Rukobia Read More »